, first quantitated by Griffiths (1975) , whereas the other factors vary in significance.
Pre-operative CA125 levels (Lavin et al., 1987; Vergote et al., 1987; Rosen et al., 1990) , post-operative levels (Redman et al., 1990; Rosen et al., 1990) , absolute levels after one , two (Sevelda et al., 1989; Redman et al., 1990) , and three (Lavin et al., 1987) cycles of primary chemotherapy, the half-life (Van der Burg et al., 1988; Hawkins et al., 1989) , and rate of fall (Rustin et al., 1989) after the first cycle of chemotherapy have all been advocated as useful prognostic indicators. Although the prognostic significance of early CA125 assay has been reported by several authors, there is no consensus yet regarding the most useful time to measure CA125.
CA125 is of undisputed value in monitoring EOC patients (for review see Jacobs & Bast, 1989) (Swenerton et al., 1985) although they have mostly been evaluated in patients with advanced disease as a result of the high incidence of this group of patients. Patients with 'advanced' EOC, however, represent a heterogeneous group, with 5 year survival varying from 7% to 62% (Marsoni et al., 1990 (Fisken, 1991 (Kaplan & Meier, 1958) and differences between curves tested using the Log rank test (Peto et al., 1977) . In all analyses CA125 and age were treated as continuous variables, whereas performance status, residual disease, ascites, adhesions and tumour grade were treated as categorised variables.
Results
Factors influencing progression free survival The value of CA 125 after one cycle ofprimary chemotherapy CA125 was not a significant predictor of either progression free or overall survival in the immediate post-operative period, but after one cycle remained significant for both progression free and overall survival throughout primary chemotherapy. Patients with CA125 levels of >50OUml-I after one cycle of chemotherapy had a very poor survival. They represented the upper quartile of the total group. Consequently, the total patient group (n = 57) was divided into quartiles based on CA125 levels to determine if further prognostic groups could be identified on this basis. Table III shows the disease characteristics of patients in each quartile. Progression free and overall survival curves were plotted for each quartile (groups A, B, C and D). It was only possible to obtain dates of progression for 38 of the 57 patients who had CA125 assayed at this time. Table IV shows the treatment regimes given to patients in each quartile, their responses and reasons for stopping treatment. The number of patients in each category who had progression dates are shown in brackets.
Prediction ofprogression free survival with CA125 Figure 1 shows the progression free survival curves for each group. The difference between the curves was significant (X2 = 9.48, df = 3, P <0.02). Three C (X2 = 6.58, df = 1, P < 0.02). (Cody & Slevin, 1989) , by limitations of current drug regimes, and increasingly by financial considerations (Rees, 1990) . When deciding whether to stop treatment in patients with no change in markedly elevated CA125 levels after one cycle of primary chemotherapy, Rustin (1991) has urged caution in that up to 10% of patients may eventually respond, and it would be wrong, he points out, to deny patients this chance however slight. Such patients may have a useful prolongation of progression free interval.
It is also worth considering that it is becoming increasingly rare for patients to be reevaluated at the end of primary chemotherapy with the prognostically informative second look (Gershenson et al., 1985) . Late on or at the end of primary therapy therefore, CA125 estimation alone could be a useful 'hard' prognostic indicator. A cost effective strategy would be to assay CA125 after the first and then at the end of a six cycle course of chemotherapy. If effective rescue regimes or agents are developed there may be a case for more frequent monitoring to permit early switching to an alternative therapy, such as taxol (Thigpen et al., 1990) .
The case for or against including early serum CA125 in prognostic evaluation of epithelial ovarian cancer to see whether its usefulness changed with time and therapy would, of course be greatly clarified by a suitable prospective study in which some of the problems which beset retrospective analyses, such as selection problems and incomplete collec-tion of data points, would be minimised. The initiation of ICON 1 and ICON 2 provides an ideal opportunity to look at CA125 prospectively in a large cohort of patients with early and advanced EOC respectively (Williams, 1992) .
